Why the study?
Does implantation of an additional transvenous HV-P/S lead improve event-free survival compared to lead replacement in patients with HV-P/S lead defects?
Population
86 patients with high-voltage pace/sense (HV-P/S) lead defect
Comparison
Implantation of an additional transvenous HV-P/S… vs Extraction of the defective HV-P/S lead and…
Design
Cohort
Follow-up
29 +/- 15 months (group 1) and 33 +/- 21 months (group 2)
Authors
Loading...
Additional lead implantation was associated with similar event-free survival as replacement; leaves open the preferred strategy for ICD lead defects.
Does implantation of an additional transvenous HV-P/S lead improve event-free survival compared to lead replacement in patients with HV-P/S lead defects?
Implantation of an additional HV-P/S lead versus replacement of the defective lead results in similar mortality and morbidity outcomes in patients with ICD lead defects.
Wollmann et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: